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software to identify potential infusion notes. We used the NLP software to extract 
drug and dosage information, and standardize results. Methods: Trained review-
ers compared the NLP extractions to source documents and judged whether the 
software correctly extracted and standardized data. The software contains a display 
window allowing reviewers to directly assess the NLP extraction. NLP was run on all 
notes, but note titles were selected for evaluation based on the likelihood of contain-
ing infusion data. Accuracy, described as the number of correct extractions divided 
by the number of reviewed notes, was used to evaluate NLP performance. NLP was 
considered acceptable when the lower bound of the 95% Confidence Interval (CI) 
reached 80% accurate. Results: The NLP was trained on 4,000 notes and the evalu-
ation phase reviewed 35,190 notes based on 255 note titles covering 93.1% of eligible 
notes. The overall accuracy rate was 94.0% [95%CI: 85.5-100%] 33,077 notes were 
correctly extracted, 1,950 failed to extract infusion data and 163 contained an incor-
rect extraction. The range of the lower bound of 95%CI for the 255 titles was 78.8-
100%; 247 (96.9%) titles had a lower bound > 80%. ConClusions: The NLP software 
demonstrated acceptable accuracy when extracting biologic DMARD infusion data 
for approximately 97% of note titles, suggesting that clinical notes are a reliable 
data source to identify biologic DMARD infusion data when coding is inconsistent.
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objeCtives: The mandated implementation of ICD-10-CM (International 
Classification of Diseases, Tenth Revision, Clinical Modification) codes in 2014 
challenges the health care community to accurately map ICD-9-CM (International 
Classification of Diseases, Ninth Revision, Clinical Modification) codes to these new 
codes, in order to preserve consistency and validity of medical conditions. The usage 
of current mapping systems, including the Centers for Medicare & Medicaid Services’ 
(CMS) General Equivalence Mappings (GEMs), is hindered by their limited definitions 
of medical conditions. Additional mappings for conditions could be complicated. 
Instead of a simple one-to-one code matching, a one-to-many or a many-to-one 
matching might be needed. A systematic approach is needed to overcome the limi-
tations and complexities. Methods: Nineteen Charlson Comorbidity Index (CCI) 
medical conditions plus 21 other conditions were chosen for mapping. CMS’ 2013 
GEMs were used whenever available. When no GEMs existed, other public and pro-
prietary mapping systems were utilized. When necessary, expertise in coding and 
clinical knowledge was leveraged to improve the mapping. Results: The 1646 unique 
ICD-9-CM codes required to fully define the 40 medical conditions, mapped to 3742 
unique ICD-10-CM codes. A total of 6355 code-to-code mappings were obtained: 1135 
(17.9%) had a one-to-one match, 3636 (57.2%) had a many-to-one match (ICD-10-CM 
less granular), 425 (6.7%) had a one-to-many match (ICD-10-CM more granular), and 
1159 (18.2%) had a more complicated, many-to-many match. No GEMs existed for 221 
code maps. ConClusions: GEMs provides a strict and limited mapping of many 
conditions necessitating additional work to fully define these conditions. When ICD-
10-CM codes are in effect, validation studies are needed to verify the accuracy of the 
proposed mappings, particularly for commonly used conditions such as CCI. The CCI’s 
reliability and specificity, particularly, must be maintained with the new ICD-10-CM 
codes in order to continue to be useful as an important research tool.
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objeCtives: Research using observational data is complex and costly due to mas-
sive size and disparate format. Consequently, scientists frequently use one data 
source when conducting a study, which can result in inaccurate reflection of the 
target population or insufficient sample sizes. Use of a Common Data Model (CDM) 
standardizes format across disparate observational databases, facilitating consist-
ent and efficient application of research methods. The objective of this study was 
to rapidly and efficiently estimate how well disparate sources reflect “known” 
population characteristics, utilizing standardized patient selection, analyses and 
visualization software on data that has been transformed into a CDM. Methods: 
Using CEWorks® software, AF patients treated with warfarin or NOA were selected 
from multiple Administrative Claims and EHR databases previously transformed 
into a CDM format. Rates of selected disease states were calculated using a CEWorks 
analysis module, and then compared to results published in a recent study. Results 
across disparate databases were imported into a visualization tool for further com-
parison among data sources. Results: Preliminary results indicate that rates of 
selected disease state across disparate databases are similar to those published 
in a previous study. Total number and percentage reported in the study for NOAC 
[10,789 - 35%] and warfarin [19,964 - 65%] patients matched comparably at 8,093 
[29%] NOAC patients and 20,133 [65%] warfarin patients in CDM version. Different 
data sources also show similar prevalence rates on selected disease state, although 
such similarities show some gaps introduced by region and other demographic vari-
ables. ConClusions: Use of a CDM enables rapid data analysis to be performed 
across multiple data sources, enabling meaningful comparisons across disparate 
data. Results are easily linked to data visualization tools for further analysis. This 
study has far reaching implications for data scientists using multiple, large data 
sources, and further study is in need to verify its practicality.
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the lowest proportion males (54%). Mean age was lowest in the hallucinogen (24 
years) and cannabis (26 years) cohorts; each consisted of 35% patients < 18. Over 
half the amphetamine cohort resided in the western and southwestern US. Major 
psychiatric comorbidity was present for 44% in the sedative cohort, compared to 
15% in the alcohol cohort. Median total post-index costs were lowest for the can-
nabis ($6,740) and alcohol ($6,830) cohorts, and highest for the sedative cohort 
($16,628). ConClusions: Patients with claims carrying diagnoses indicative of 
AUD/SUD are a highly heterogeneous group in terms of drug of abuse, demographic 
and clinical characteristics, and health care costs and utilization. Measures combin-
ing AUD and SUD patients may be more reflective of alcohol than other substances 
because AUD patients predominate.
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objeCtives: Researchers use the Healthcare Cost and Utilization Project (HCUP) 
Cost-to-Charge Ratio (CCR) File to translate total charges in the Nationwide Inpatient 
Sample (NIS) into accurate costs. We investigated the impact on cost estimates 
using four techniques for handling missing CCRs. Methods: This is a cross-sec-
tional study using nationally-representative hospitalization data in the US in 2011. 
We investigated four techniques including: 1) complete case analysis; 2a) using 
a reweighting technique recommended by HCUP; 2b) reweighting by adjustment 
cells; and 3) using hotdeck imputation by adjustment cells. We used five disease 
cohorts chosen to represent different sample sizes. We created a disease cohort 
data set with non-missing CCRs as a benchmark complete data set. We picked one 
state at a time and set their CCRs to missing to create a data set with missing CCR 
data. We compared the CCR-adjusted cost estimates (mean and total) from both 
data sets. To evaluate the quality of an estimator, we assessed bias, variance, and 
the mean squared error (MSE) of an estimator. Results: The range of missing rates 
was 1%-12%. The majority of states (> 84%) had missing CCR data in the range of 1% 
to 4%. In general, biases in magnitude and MSE of mean adjusted costs increased as 
missing rates increased. Complete case analysis, the reweighting technique recom-
mended by HCUP, and reweighting by adjustment cells performed similarly in mean 
cost estimation. Reweighting techniques performed better in total cost estimation. 
Complete case analysis underestimated total costs and became worse as missing 
rates increased. ConClusions: In NIS data, to handle missing CCRs, when miss-
ing data < 4%, researchers will obtain similar mean cost estimates using complete 
case analysis, the reweighting technique recommended by HCUP, or reweighting by 
adjustment cells. However, if total cost is the estimate of interest, researchers should 
adopt either reweighting techniques in order to avoid underestimation.
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objeCtives: While patients with end-stage renal disease (ESRD) represent only 1 
percent of Medicare beneficiaries, this population accounts for 8 percent of total 
Medicare spending. The disproportionate cost of treating ESRD has resulted in a high 
level of monitoring and policy focus. A number of public databases currently exist 
for study of the ESRD program in the US, but these databases are difficult to use and 
integrate for policy analysis of this program. Objective was to develop an integrated 
ESRD “data warehouse” with GIS capabilities from publicly-available dialysis patient 
and provider data and general population statistics, to enable a broadened scope of 
applications for policy analysis. Methods: ESRD-related datasets were collected 
from Medicare sources and integrated into a relational database management sys-
tem. Datasets included Renal and Hospital Cost Reports, Dialysis Facility Reports, 
the Dialysis Facility Compare database, and patient prevalence reports. Dialysis 
provider and patient addresses were geocoded and linked to spatial data files and 
general population data obtained from Census Bureau websites. Validation and 
outlier handling rules were created for most data and were applied either during 
the build/update process or at the point of analysis. Longitudinal datasets were 
created for trend analysis. Data are updated quarterly to keep the database cur-
rent. Results: The ESRD provider database contains over 6000 cost, utilization, 
quality, demographic and geographic variables, covering 100% of current Medicare 
ESRD providers (N= 6288 facilities). Approximately 9% are hospital-based units and 
91% are free-standing facilities. Depending on data source, the database covers 
between 6 and 14 calendar years (2001-14). Quality of the data varies, but for most 
applications, outlier and missing observations are less than 10%. ConClusions: 
Public datasets of ESRD-related information can be integrated with general popula-
tion data and a GIS to support high-quality and cost-effective economic and clinical 
policy studies that would not otherwise be feasible.
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objeCtives: Infusions of outpatient medications including biologic Disease 
Modifying Anti-Rheumatic Drugs (DMARDs) administered at Veterans Health 
Administration (VHA) facilities are well documented in the electronic medical 
record but data are not consistently entered into the pharmacy dispensing or nurse 
administration structured data sources. Although CPT codes can be used to identify 
many infusion events but inconsistent coding does not allow estimation of the 
administered dose. To address this, we developed Natural Language Processing (NLP) 
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potential differences which should be considered when selecting data to answer 
specific research questions.
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objeCtives: Real world evidence (RWE) is critical for the assessment of health 
technologies. This study was conducted to define and compare the governance 
of, and data sources available for, real world research (RWR) in Latin America (LA) 
and Canada. Methods: Systematic literature review was conducted to exam-
ine administrative and clinical data for 10 major countries ranked by population. 
Research terms were defined by an international team, and reports were reviewed 
and assessed for content, quality and bias by two investigators. Data was sum-
marized in major and minor domains for each country. Results: Governance of 
RWR differed between countries, both from a regulatory and an ethics committee 
review perspective. Regulatory review was required for non-interventional studies 
in 4/10 countries. Ethics review varied importantly in complexity, site (local, cen-
tral) and duration (which could exceed 1 year). Administrative and clinical search 
terms returned over 1800 reports from LA, principally from Brazil, Mexico, Argentina 
and Chile, of which over 700 contained contributory information on data sources 
for RWE. Of these, 156 addressed international registries or databases including 
countries in LA, 245 reported national registries or databases within one country in 
LA, and 308 reported registries or databases from a single or multiple institutions 
within a country. Principal administrative categories included claims, prescription 
and economic data sources, while principal clinical categories included data sources 
relating to cancer, cardiology, neurology, respirology, and diabetes. In contrast, a 
total of over 2000 reports were obtained for Canada alone, with a similar categorical 
distribution to that observed in LA. ConClusions: Latin America is a region with 
diverse health systems, inputs and outcomes. While sources for RWE exist in sev-
eral larger countries, comprehensive national or regional databases are uncommon 
compared with a mature public health care system such as Canada. Improvement 
of database quality and well-designed prospective population studies are critical 
to enhance the RWE base.
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bACkgRound: Real-world data are required to fully assess the value of treatments 
in clinical practice. Given the importance of having all available data to make this 
assessment, while ensuring efficiencies in preventing duplication of data collection, 
the absence of a central repository of longitudinal data sources on cancer patients 
in Europe remains a challenge. objeCtives: i)Identify and characterize existing 
traditional and non-traditional data sources on lung cancer and renal cell carcinoma 
(RCC) patients in Europe; ii)Determine the utility of each identified data source 
for real-world research. Methods: A systematic literature search was conducted 
using MEDLINE and Embase(01/01/06-20/12/13). MeSH and Emtree terms included 
the following concepts: lung cancer (small-cell and non-small-cell), RCC, real-world 
data (registry, cohort, etc), and European countries. Clinical trials, case reports, case 
series, literature reviews were excluded. Identified abstracts were screened and 
reviewed based on relevance to key concepts. For each data source, utility was 
assessed using the following variables: country, setting, type (e.g. registry, EMR, 
etc.), clinical and baseline characteristics, tumor, biomarkers, test results, treat-
ments, clinical and patient reported outcomes, resource utilization. Results: The 
search yielded 2,478 abstracts for lung cancer and 698 for RCC. Following screening, 
192(7.7%) and 102 (14.6%) were retained respectively. Data sources for lung cancer 
were equally distributed between general cancer and tumor specific registries. Most 
originated from the UK (33.3%) or France (13.8%). RCC data sources were primarily 
tumor specific and local with population size ranging from 56-1800. Data sources 
originated from Italy (22.5%), France, UK, and Germany (each 16.7%). Gap analyses 
with respect to the availability of specific data elements and utility for outcomes 
research will be presented. ConClusions: Data sources on cancer are highly frag-
mented in Europe, especially for RCC, emphasizing the need for database mapping. 
Completeness and consistency of the data elements needed to support technology 
assessments are variable.
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objeCtives: To establish quality of care benchmark estimates (HEDIS, PQA, or NQF) 
for Asthma, COPD, and Diabetes in the US Commercial Employer Sponsored Health 
Insured Population (EIS) for 2011. Methods: The Marketscan Commercial claims 
database from 2010-2011 was used to identify the EIS population during 2011 and 
those patients with Asthma, COPD, and Diabetes. Patients needed at least 6 months 
of continuous coverage during 2011 and coverage during December 2011. Asthma, 
COPD, or Diabetes must have been recorded during 2011 or in the 6 months prior and 
was identified using a clinically approved coding algorithm. A weight was assigned 
objeCtives: Capturing dosing of biologic and non-biologic Disease Modifying Anti-
Rheumatic Drugs (DMARDs) using electronic medical records is challenging. Precise 
estimates of weekly dose using structured pharmacy data alone are difficult since 
quantity dispensed is not standardized for injectable products. Natural Language 
Processing (NLP) software was developed to extract elements of the prescribing 
provider’s medication instructions (SIGs) to compute the average weekly dose. The 
objective was to evaluate the accuracy of the NLP software’s computation of the 
average weekly dose by medication and route. Methods: The NLP software com-
puted the average weekly dose for biologic and non-biologic DMARDs and was 
evaluated against the annotator-derived reference standard. Using an annotation 
guideline, trained annotators annotated relevant information from SIGs including 
unit strength, dose per administration event and the schedule of administration 
events. The NLP software was then trained on 11,937 records. A validated set of the 
annotator-derived reference standard that contained 140 SIGs per medication and 
route was used to evaluate the NLP accuracy and compute the 95% Confidence 
Interval (CI) of accuracy. Results: The overall accuracy for injectable biologic and 
oral and injectable non-biologic DMARDs was 89.1% (95% CI: 87.9%-90.3%). Accuracy 
was 95.3% (95% CI: 91.9%-98.7%) for oral methotrexate, 84.7% (95% CI: 78.9%-90.5%) 
for injectable methotrexate, 87.9% (95% CI: 82.5%-93.3%) for sulfasalazine, and 92.9% 
(95% CI: 88.7%-97.2%) for hydroxychloroquine. For biologics, accuracy was 92.1% 
(95% CI: 87.6%-96.6%) for etanercept, 98.6% (95% CI: 96.7%-100%) for adalimumab 
and injectable abatacept 90.0% (95% CI: 85.2%-94.8%). The lower bound of the 95% CI 
ranged from 79.1%-100% for biologic DMARDs and from 78.9%-91.9% for non-biologic 
DMARDs. ConClusions: The lower bounds of the 95% CI for most medications 
were greater than 80%. These results indicate that the NLP software can be used to 
extract information to calculate the weekly dose of DMARDs from narrative medi-
cation schedules.
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objeCtives: Private claims databases have been a rich source of information related 
to health care delivery, though the fragmented nature of U.S. health insurance 
market limits their ability to provide a comprehensive view of a given geography. 
Additionally, claims data are often expensive (> $25,000) - restricting access to those 
with the economic means to afford it. To provide a more thorough view of health 
costs and practice at the state level, 11 states have created all payer claims databases 
(APCDs). An analysis was conducted to review their designs and consider how they 
will impact health economic analyses and health services research. Methods: 
A detailed review of 11 APCDs was conducted using a combination of secondary 
research and key informant interviews. This included reviewing the legislation that 
mandated and funded their creation, the rules under which they operate, and the 
data they collect and make available. The multi-state analysis was then informed 
by a deeper analysis of the data integration opportunities, reporting abilities, and 
costs for data exchange for Maine’s newly revised APCD. Results: Across states, 
APCDs make publicly available a wide array of health data in a manner that ensures 
privacy and security of personal health information. Each APCD provides varying 
levels of granularity in health care resource utilization, demographic comparisons, 
expenditures, and quality/safety data. Ability to customize data pulls is growing, 
though private claims datasets appear to have greater flexibility. In Maine’s APCD, 
commercial and Medicaid medical, pharmacy, and dental data are available to 
researchers, with quarterly block releases and opportunities for individual que-
ries. ConClusions: APCDs are providing researchers with an open-access, afford-
able pathway to understand health care resource utilization and practice across 
entire populations. As more come online, greater participation in health economic 
and health services research can be expected.
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objeCtives: Lung cancer (LC) leads cancer-related mortality in the U.S.; often 
diagnosed at an advanced stage with poor prognosis. Non-small cell lung cancer 
(NSCLC) accounts for approximately 85% of all LC. Real-world research in NSCLC 
necessitates clinical and longitudinal detail typically unavailable from any single 
retrospective data source. This study describes and benchmarks a comprehensive 
disease record for NSCLC patients created by linking the PharMetrics Plus (PMTX) 
database to an oncology electronic medical records (OEMR) database. Methods: 
Adult NSCLC patients (ICD-9-CM code 162.2 to 162.9) with either confirmed histol-
ogy, use of pemetrexed, or without evidence of etoposide use were identified from 
PMTX and OEMR databases between 1/1/2006 and 7/31/2013. Patients were linked 
using a HIPAA-compliant encryption algorithm. Key patient characteristics from the 
linked sample were compared with the National Cancer Institute SEER registries 
NSCLC population (2006-2010, n= 152,465). Results: 182,425 NSCLC patients were 
identified (PMTX:156,029; OEMR:26,906), with 510 patients linked to both databases. 
Among linked patients, 50% were female, 36% were considered non-squamous (con-
firmed by histology or use of pemetrexed) and 47% were metastatic at diagnosis. 
Treatment data (surgical resection, radiation, or chemo/biological therapy) were 
available for 97% of the linked patients; 64% with platinum and 30% with pem-
etrexed therapy. The SEER population had a higher proportion of patients > = 65 
years at diagnosis (64% vs. 25%) but a lower portion (21%) metastatic at diagnosis 
compared to the linked sample. ConClusions: This study demonstrates that data-
bases can be linked to provide a longitudinal, clinically rich view of an NSCLC popu-
lation. Comparisons between the linked sample and the SEER population highlight 
